The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
TBCRC 002: A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer.
Andres Forero-Torres
Research Funding - Genentech; Novartis
Hope S. Rugo
Research Funding - Genentech/Roche; Novartis
Christos Vaklavas
No relevant relationships to disclose
Nancy U. Lin
Research Funding - Genentech
Lisa A. Carey
Research Funding - Genentech; Novartis
Minetta C. Liu
Honoraria - Genentech
Research Funding - Genentech
Rita Nanda
Research Funding - Genentech
Shannon Puhalla
No relevant relationships to disclose
Anna Maria Storniolo
No relevant relationships to disclose
Helen Krontiras
No relevant relationships to disclose
Mansoor N. Saleh
Research Funding - Genentech
Yufeng Li
No relevant relationships to disclose
Albert F. LoBuglio
No relevant relationships to disclose
Jennifer F. De Los Santos
No relevant relationships to disclose